. We further tested the correlation between GPAGs and vessel normalization in liver cancer. CD31
+ tumour-associated endothelial cells (TECs) or the matched CD31
+ normal endothelial cells from the same patient were profiled (Extended Data Fig. 1a ). Compared to normal endothelial cells, TECs express decreased GPAGs and increased PPAGs (Extended Data Fig. 1b ). In the GSE20017 dataset, (∑ GPAGs − ∑ PPAGs) inversely correlates with 'invasive vasculature' (Extended Data Fig. 1c ). Thus, (∑ GPAGs − ∑ PPAGs) is a vessel normalization indicator.
In breast cancer, GPAGs correlate with immune response pathways (Fig. 1d, Supplementary Table 3 ), especially T-cell receptor (TCR) signalling (Fig. 1e, f) . Similarly, in the GSE51401 dataset, (∑ GPAGs − ∑ PPAGs) in TECs correlated with TCR signatures in non-TECs from the same tumours (Extended Data Fig. 1d, e) .
To investigate the relationship between T lymphocytes and vessel normalization, we examined mammary tumours in various host strains that lacked pericytes or T lymphocytes. We orthotopically transplanted E0771 mouse tumour cells into mice expressing both NG2-CreER TM (tamoxifen-inducible Cre recombinase under the control of the NG2 (also known as Cspg4) promoter/enhancer) and Cre-inducible diphtheria toxin receptor (mice denoted as Peri Del ). Upon tamoxifen and diphtheria toxin treatment, NG2
+ pericytes were significantly reduced (Extended Data Fig. 2a, b) , which caused a decrease in total infiltrating immune cells, consistent with previous findings 4 . T lymphocytes were particularly decreased, whereas CD11b
+

CD11c
− cells remained unchanged (Extended Data Fig. 2c, d ), suggesting that vessel normalization preferentially promotes infiltration of T lymphocytes.
To investigate any reciprocal effects of T lymphocytes on vessel normalization, we transplanted E0771 cells into animals with knockout of CD4 (CD4 Area of lung metastasis (%) 0 P = 0.037 P = 0.0079
We further validated the effects mediated by CD4 + T lymphocytes (CD4 + -TLs) on vessel normalization in other models with varying baseline CD4 + -TL frequencies. CD4 KO in 4T1 tumour-bearing mice led to decreased pericyte coverage and alterations related to vessel normalization disruption, including enhanced hypoxia, increased dextran leakage, and reduced lectin perfusion (Extended Data Fig. 3a-g ). We also used anti-CD4 antibodies to deplete CD4 + -TLs. This can be administered in an acute manner (Extended Data Fig. 3h ) to delineate roles of CD4 + -TLs in different metastasis stages. A regimen that restricts anti-CD4 effects to orthotopic tumours increased later metastasis formation (Extended Data Fig. 3i-k) , showing that anti-metastasis functions of CD4 + -TLs begin in orthotopic tumours. Another model, AT3, has a lower baseline T lymphocyte infiltration (Extended Data Fig. 3l ). CD4 KO resulted in reduced pericyte coverage and enhanced hypoxia (Extended Data Fig. 3m, n) . However, dextran leakage and lectin perfusion efficiency were not altered (Extended Data  Fig. 3o, p) , which may be due to the already low level of CD4 + -TLs. Two further models, T11 and T1, from a collection of p53-null tumour lines 8 , had high and low baseline CD4 + -TL infiltration, respectively (Extended Data Fig. 3q ). CD4
KO significantly increased hypoxia in T11, but did not affect the already high hypoxia level in T1 (Extended Data Fig. 3r ).
To determine whether CD4 + -TLs also regulate vessel normalization in normal tissues, we examined mammary glands and lungs of tumourfree mice. There was no difference in vascular structures between wild-type and CD4 KO mice (Extended Data Fig. 4a, b) . Wounded tissues trended towards lower pericyte coverage in CD4 KO mice (Extended Data Fig. 4c ). As tumour microenvironment may resemble wound healing 9 , the vessel normalization effects of CD4 + -TLs may have initially evolved to cope with wound healing.
We next investigated whether CD4 + -TL activation is required for vessel normalization. We conditionally knocked out class II major histocompatibility complex (MHC-II) by combining mice expressing Tie2-Cre (in which Tie2 (also known as Tek) promoter drives expression of Cre recombinase) and H2Ab floxP/floxP (M-II KO ). Because Tie2 is required for post-natal haematopoiesis, MHC-II was deleted in professional antigen-presentation cells, but not in the thymus, leaving positive selection intact (Extended Data Fig. 5a-e) . Although 5-10% of pericytes and < 1% of TECs also express MHC-II, they only account for 0.1% of all MHC-II + cells and are unlikely to influence the immune microenvironment (Extended Data Fig. 5f, g ). This conditional knockout reduced activated CD4 + -TLs, decreased the ratio of effector memory to naive cells, but did not alter total numbers of CD4 + -TLs (Extended Data Fig. 5h-j) . Moreover, among CD4 + -TL subsets, only interferon-γ (IFNγ )
+ T H 1 cells were substantially decreased (Extended Data Fig. 5k ).
Tumours in M-II KO mice phenocopied those in CD4 KO or Peri Del mice with decreased pericyte coverage (Extended Data Fig. 6a ), increased vascular leakiness (dextran and Evans blue assays, Extended Data Fig. 6b, c) , decreased lectin perfusion (Extended Data Fig. 6d ), increased hypoxia (nuclear HIF-1α and pimonidazole staining, Extended Data Fig. 6e, f) , and decreased infiltration of immune cells except for neutrophils, which were increased (Extended Data Fig. 5l ).
To study molecular mechanisms, we performed RNA sequencing (RNA-seq) on TECs (Extended Data Fig. 7a ), the central cell type that A n t i-I g G A n t i-P D 1 A n t i-C T L A 4
A n t i-P D 1 a n t i-C T L A 4
A n t i-I g G Fig. 7b-d) . It also changed pathways and genes known to regulate vessel normalization 10 , including increased Vegfa, decreased Angpt1/Angpt2, and decreased adhesion and extracellular matrix molecules (Extended Data Fig. 7e-h ). Collagen IV staining revealed discontinuous TEC extracellular matrix in CD4 KO mice (Supplementary Videos 1-4). We also examined Sphingosine-1-phosphate (S1P) and its precursors, ruling out a role of S1P pathway in CD4 + -TL-mediated vessel normalization (Extended Data Fig. 7i, j) . Thus, CD4 + -TLs regulate multiple pathways related to vessel normalization in TECs.
To determine whether activated T lymphocytes co-localize with TECs, we adoptively transferred both stimulated CD4 We reasoned that immune checkpoint blockade (ICB) should be immunostimulatory and thereby enhance vessel normalization. We used CD8 KO mice to separate CD4 + -TLs from CD8 + -TL-mediated cytotoxicity. Interestingly, even without CD8 + -TLs, combinatory inhibition of PD1 and CTLA4, two clinically relevant ICB targets 11 , significantly delayed orthotopic E0771 tumour growth. In size-matched tumours, ICB led to increased pericyte coverage (Fig. 3a, b ) and decreased pulmonary metastasis (Fig. 3c) .
In addition to tumour size-matched experiments, we performed time-matched experiments (Extended Data 3 )
H (Human) n = 35; P (PDX) n = 25
Hypoxia after T H 1 AdT FC after T H 1 AdT letter reSeArCH encoding endothelial adhesion molecules, ICAM1 and SELE (Extended Data Fig. 10a) , which mediate immune cell infiltration 12 . IFNγ also decreased endothelial VEGFA, and increased CXCL9, CXCL10 and CXCL11 (Extended Data Fig. 10a, b) Fig. 10c ). This procedure improved pericyte coverage (Extended Data Fig. 10d) , and increased infiltration of host CD45.2 + immune cells including CD4 + -TLs, macrophages and dendritic cells (Extended Data Fig. 10e, f) . Neutrophils exhibited an opposite trend (Extended Data Fig. 10g ), similar to previous experiments (Extended Data Figs 5l, 9e, f). Pericyte depletion attenuated these effects (Extended Data Fig. 10e, f) , confirming the role of pericytes in this positive feedback loop (Extended Data Fig. 10h) .
Patient-derived xenograph (PDX) models provide an opportunity to establish the causal role of T H 1 cells in vessel normalization for human tumours, because tumours were transferred from an immunocompetent (original patients) to an immunodeficient (animals) environment. We analysed gene expression profiles of PDX-original tumour pairs of multiple cancer types. GPAGs and PPAGs were not comparable owing to inter-species differences. Mouse stroma cell genes could not be captured by human microarray platforms, or were removed when aligned to human genomes in RNA-seq analyses. However, hypoxia-related signatures in human cells can reflect vessel normalization, which were indeed enriched in PDX tumours as compared to the matched or un-matched human tumours (Fig. 4a, b) . We first used human MDA-MB-231 tumours for adoptive transfer of T H 1cells. Tumours with T H 1 transfer had higher expression of IFNγ (Fig. 4c) , confirming successful infiltration. T H 1 cells induced vessel normalization, as indicated by decreased hypoxia and vessel leakiness, pruning of large/dilated vessels, and improved perfusion efficiency (Fig. 4d-g ). Molecularly, Angpt2 and other VEGF-signature genes 15 decreased (Fig. 4h) . We also applied this strategy to nine PDX models, seven of which responded to T H 1 cell transfer with reduced hypoxia. The two non-responders expressed VEGF signatures at a lower baseline level, and correspondingly displayed a low starting level of pimonidazole (Fig. 4i) , suggesting that the lack of response is due to initially low VEGF signalling and/or hypoxia.
Finally, we investigated whether the connection between CD4 + -TLs and vessel normalization can be generalized to other cancer types. In the TCGA database, we analysed nine solid tumour types. In seven of these, estimated CD4 + -TL infiltration (CIBERSORT 16 ) and hypoxia were inversely correlated. In eight, CD4 + -TL infiltration and (∑ GPAGs − ∑ PPAGs) were positively correlated (Fig. 4j) .
Although T lymphocytes have previously been linked to angiogenesis [17] [18] [19] , their effect on vessel normalization has not been appreciated. Therefore, our finding adds to the growing list of T lymphocyte functions. Multiple lines of evidence show that stimulated CD4 + -TLs, especially T H 1 cells, probably mediate vessel normalization by localizing to the vicinity of TECs, changing the cytokine environment, and subsequently affecting pericyte recruitment/attachment. Vessel normalization, in turn, alters the immune landscape by recruiting T lymphocytes and decreasing neutrophils. At a molecular level, this mutually regulatory loop is orchestrated in part by IFNγ and CD40L, through their effects on multiple downstream pathways. Our results argue that ICB efficacies may be achieved partially through T H 1-cell-mediated vessel normalization. A recent finding demonstrated that IFNγ signalling is essential for therapeutic responses to ICB therapies 20 . Anti-angiogenesis therapies have also been extensively tested in the clinic 21 . The clinical outcomes of these therapies may partially depend on their effects on vessel normalization and the consequent reprogramming of immune microenvironment. It is conceivable, for instance, that improving vessel normalization will increase immune cell infiltration and enhance the efficacies of immunotherapies such as anti-PD1 or anti-CTLA4 antibody treatments. Thus, combinatory interventions that simultaneously perturb both processes may present promising strategies for potential synergy. KO and CD8 KO mice with BALB/c background, the CD4 KO and CD8 KO B6 mice were crossed with wild-type BALB/c mice for eight generations and four generations, respectively.
For retro-orbital injection, the mice were anaesthetized using an isofluranebased small animal anaesthesia unit. Otherwise, ketamine (100 mg kg ) were used for anaesthesia. 6-8-week-old female mice were used unless otherwise specified. No randomization or blinding was used to allocate experimental groups. No statistical methods were used to predetermine sample size.
All animal work was done in accordance with a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. The tumour weight did not exceed 10% of animal's body weight. All the tumours used in the project meet this criterion. The information associated with tumour size/weight can be found in the Source Data (for Figs 2a, 3a, c, Extended Data Figs 3l, 5i, 9b , 10d, and Supplementary Table 4 ; available with the online version of the paper). PDX tumours. Breast cancer PDXs were maintained by injecting 1-2-mm-sized tumour pieces into fat pad-cleared mammary glands of NSG mice. The development of PDX lines was conducted under the Institutional Review Board-approved protocols, and was documented in previous studies 22 . The current study used already-established PDXs that had been de-identified, and therefore, has been granted protocol exemption by the Institutional Review Board of Baylor College of Medicine for not involving human subjects. In vivo treatment. Mice were injected with 1 mg tamoxifen (Sigma) each day for 4 consecutive days. For diphtheria-toxin-mediated cell depletion, 100 μ g kg −1 of diphtheria toxin (Sigma) were injected intraperitoneally as indicated in the appropriate figure legends.
To deplete CD4 + -TLs, mice were injected intraperitoneally with 250 μ g anti-CD4 (clone GK1.5) or 250 μ g isotype-matched control antibody (rat IgG2b (clone LTF-2; both from BioXcell)) on day 3 and day 1 before tumour inoculation.
For immune checkpoint blockade therapy, 125 μ g anti-CTLA-4 (clone 9D9) and 125 μ g anti-PD-1 (clone RMP1-14), or the same amount of isotype-matched control antibody (mouse IgG2b (clone MPC-11) and rat IgG2a (clone 2A3; all from BioXcell)) were intraperitoneally delivered to mice on day 1 and day 8 after tumour inoculation. Mammary fat pad injection. E0771 cells were collected from culture with 2 mg ml −1 EDTA (Versene, Lonza). 4T1 cells, AT3 cells, and MDA-MB-231 cells were collected using 0.25% trypsin (HyClone). The cells were washed twice with PBS (Lonza), counted, then resuspended in 1:1 solution of PBS and Matrigel (Phenol Red-Free and growth factor reduced; BD Bioscience). Mice were anaesthetized, and a small incision was made on the shaved abdomen to reveal the mammary gland. 0.5 × 10 6 E0771, 0.2 × 10 6 4T1, 0.2 × 10 6 AT3 or 10 6 MDA-MB-231 cells were injected directly into the mammary fat pad. The incision was then closed using wound clips (EZ Clips), which were removed on day 8 after injection of cancer cells.
For the primary mouse tumour models derived from p53 null BALB/c mice (T11 and T1) and patient-derived xenografts, tumours were minced into approximately 1 mm 3 fragments and were transplanted directly into fad pads of BALB/c and NSG mice, respectively. The 3-4-week-old NSG mice were used for patient-derived xenograft transplantation after clearance of mammary gland epithelium cells. Primary tumour resection. Primary tumour growth was monitored every two days by measuring tumour length (L) and width (W). Tumour volume (V) was then calculated using the formula, V = π × L × W 2 / 6. E0771 tumours were surgically resected when tumour size reached a volume greater than 500 mm 3 (around day 12-14 after injection), whereas 4T1 tumours were removed when the size was larger than 200 mm 3 (around day 9-12 after injection). The lymph nodes were also removed at the time of tumour resection. Wound closure assay. For wound healing experiments, 8-10-week-old female mice of different inbred strains (BALB/c and C57BL/6J) with different genetic backgrounds (wild type, CD4 KO , and CD8 KO ) were anaesthetized and 3-5 mm full-thickness wounds were made on the shaved dorsal skin with sharp-blunt scissors. The mice were monitored daily until wound closure was completed (around day 10-12 after wounding). Skin tissues were collected and fixed with 4% paraformaldehyde (PFA) overnight at 4 °C for immunofluorescence analysis. Bioluminescent imaging and analysis. Mice were injected retro-orbitally with 1.5 mg of d-luciferin (Thermo Fisher) (15 mg ml −1 in PBS). Imaging was completed within 2-4 min after injection, using a Caliper Living Imaging system and analysis software v4.2. For the bioluminescence image plots, photon flux was calculated for each mouse by using a rectangular region of interest encompassing the thorax of the mouse in a supine position. Tumour dissociation. Tumours were cut into small fragments (around 1 mm 3 ) and incubated for 20 min with Collagenase type III (Worthington Biochemical), in RPMI-1640 medium containing 2% FBS (10 ml per g of tumour tissue) at 37 °C.
The tumour pieces were transferred to a tissue digestion C-tube (Miltenyi) and further dissociated enzymatically and mechanically on a gentleMACS Dissociator (Miltenyi). Briefly, the 'impTumour_03' program was run on the dissociator, followed by a 10-min incubation at 37 °C. Next, the 'm_Lung_02' program was run to maximize extraction of pericytes and endothelial cells, followed by a 10-min incubation at 37 °C. After a final run of the 'm_Lung_02' program, the digestion reaction was stopped with albumin-rich buffer (RPMI-1640 medium containing 0.5% bovine serum albumin (BSA)) (Miltenyi). A single-cell suspension was obtained by filtering through a 70-μ m cell strainer.
Single-cell suspensions were centrifuged for 5 min at 350g, resuspended in RBC lysis buffer (eBioscience), incubated on ice for 2 min, and washed with PBS containing 1.5% FBS (or without FBS if the downstream flow cytometry staining panel included a Ghost Dye (Tonbo)). Thymus dissociation. Mice were euthanized, and both thymuses overlying the heart were removed, minced into smaller pieces, and transferred to C-Tubes. Liberase TH/DNase I (RPMI-1640 medium containing 0.05% w/v of Liberase TH and 100 U ml −1 of DNase I (both from Sigma)) were used for enzyme solution 23 . The thymus samples were mechanically disrupted using the 'm_spleen_02' program on the GentleMACS Dissociator, followed by 15 min of digestion at 37 °C in the above enzyme solution. Following digestion, the samples were again dissociated using the 'm_spleen_01' program. The reactions were halted using albumin-rich buffer, and single-cell suspensions were obtained as described in the 'Tumour dissociation' section. amphotericin B, 55 μ mol l −1 β -Mercaptoethanol (Sigma), 10 ng ml −1 IL-2 (R&D Systems)). For T H 1-skewed stimulation, 10 μ g ml −1 anti-IL4 antibody (clone 11B11) and 20 ng ml −1 IL-12 (both from Tonbo)) were added to the medium. The cells were incubated at 37 °C with 5% CO 2 for 96 h.
If cell tracking was required, the CD4 + -TLs were labelled with CFSE (Thermo Fisher) using a mouse lymphocyte optimized method 24 . Mice received intravenous injection of 10 6 CD4 + -TLs unless otherwise noted. Evans blue assay and clonogenic assay. The assay was modified on the basis of the published protocols 25, 26 . Tumour-bearing mice were injected with 0.5 mg Evans blue dye (5 mg ml −1 in PBS; Sigma) retro-orbitally. After 2 h to allow the dye to circulate, the mice were euthanized, and a vertical inline incision along the sternum was made to expose the heart and lungs. Whole-animal perfusion was performed. An incision was made in the right atrium and 10 ml PBS containing 2 mmol l −1 EDTA (Millipore) was injected through the left ventricle to remove intravascular Evans blue dye. The tumours were resected, with the surrounding normal tissues removed. The tumours (0.2-0.5 g) were cut into pieces (< 3 mm 3 ), and incubated in 0.5 ml formamide (Sigma) for 24 h at 56 °C to extract the Evans blue from the tumour. The samples were then centrifuged at 12,000g for 5 min to pellet any remaining tissue fragments. The supernatant was collected and diluted with formamide, to a final concentration of 0.5 g tumour per ml formamide. The sample absorbance was measured at 655 nm and 750 nm against a blank containing pure formamide, using iMark Microplate Reader (BioRad). The following formula letter reSeArCH was used to eliminate the effect of residual haem pigment in the blood: corrected absorbance (A) 620 nm = A 655 nm − (1.426 × A 750 nm + 0.03).
For the clonogenic assay, blood was collected by whole-animal perfusion into 15 ml EDTA-coated conical tubes and centrifuged at 350g for 5 min. The cell pellet was incubated with RBC lysis buffer on ice for 8 min, washed twice with PBS, then resuspended in RPMI complete medium (containing 10% FBS, 100 IU ml −1 penicillin/streptomycin, and 25 ng ml −1 amphotericin B). After incubating at 37 °C with 5% CO 2 overnight, the cell culture medium was discarded, the plate was washed three times with PBS, and fresh cell culture medium was added. After culturing for an additional 8 days, the cell culture medium was removed and the plate was washed once with PBS. Then, the cells were fixed with 2% PFA for 20 min, stained with 1% Crystal Violet Solution (Sigma) for 1 min and washed with water. The plate was dried at 20 °C, and then scanned at 1,200 dpi, using GelCount (Oxford Optronix). The number of colonies was counted manually and the colony areas were measured using ImageJ. The calibration of circulating tumour cells based on clonogenic sizes can be found in Supplementary Table 5 . Lung metastasis quantification. Haematoxylin and eosin (H&E) staining and India Ink assay were used to quantify lung metastasis.
For H&E staining, mice were euthanized and were injected with 5 ml 10% neutral buffered formalin into the trachea. The lungs were removed, fixed with 10% neutral buffered formalin and paraffin embedded. For each lung sample, six 3-μ m paraffin-embedded sections at 300-μ m intervals were used for H&E staining. Images of whole-lung sections were captured using PathScan Enabler IV (Meyer), and metastases were quantified using the texture segmentation algorithm of MATLAB v2014b.
For the India Ink assay, mice were euthanized and injected with 5 ml India Ink (15% v/v diluted in PBS; Hardy Diagnostics) into the trachea. The lungs were then removed and fixed with Fekete's solution (for 1 l, mix 880 ml 70% ethanol, 80 ml 37% formaldehyde, and 40 ml glacial acetic acid) overnight at 4 °C. The lung metastasis nodules were counted manually. Pimonidazole staining and blood vessel leakiness analysis. For hypoxia studies, 2 mg pimonidazole (Hypoxyprobe) was injected intravenously and was left to circulate for 20 min before tumour resection. Staining of tumour sections was performed with a Hypoxyprobe Plus Kit according to supplier's protocol.
For the evaluation of vessel leakiness, mice were given 1mg of 70-kDa lysine fixable fluorescein labelled dextran (Thermo Fisher) and 50 μ g DyLight 649 labelled tomato Lectin (Lycopersicon esculentum; Vector Labs). After 10 min, the mouse was subjected to whole-animal perfusion as described in the 'Evans blue assay' section. The tumours were carefully excised and cut into two halves along the maximum diameter. Both halves were fixed with 4% PFA overnight at 4 °C, and were paraffin embedded or frozen. Flow cytometry. Single-cell suspensions were prepared as described in the 'Tumour dissociation' section. The cells were incubated for 15 min at 4 °C with anti-mouse Fc-block CD16/32 antibody (clone 93, eBioscience, 1:100), in PBS/FBS. Cells were subsequently stained with antibodies to detect endothelial cells, pericytes, and immune cells diluted in PBS/FBS, at 4 °C for 25 min. The following antibodies against mouse antigens were used: anti-NG2 (1E6.4) and anti-EpCAM (caa7-9G8) (both from Miltenyi); anti-CD31 (MEC13.3), anti-CD45.1 (A20), anti-CD45.2 (104), anti-IFNγ (XMG1.2), anti-IL4 (11B11), anti-IL17A (TC11-18H10.1), anti-FoxP3 (MF14), anti-MHC-II (M5/114.15.2) (all from Biolegend); anti-CD25 (eBio7D4), anti-CD3ε (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7) (all from eBioscience); anti-B220 (RA3-6B2), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-CD45 (30-F11), anti-CD62L (MEL14), anti-F4/80 (BM8) (all from Tonbo); anti-SiglecF (E50-2440, BD Biosciences).
For intracellular staining of the regulatory T cells (T REG cells) and T helper cells, CD45 MicroBeads (Miltenyi) were used to enrich tumour-infiltrating immune cells. T REG cells were detected using Foxp3/Transcription Factor Staining Buffer Set (eBioscience) as per manufacturer's instructions. For cytokine intracellular staining, 0.5 × 10 6 enriched tumour-infiltrating immune cells were resuspened in 0.1 ml RPMI complete medium (RPMI-1640 medium containing 10% heat inactivated FBS, 100 IU ml −1 penicillin/streptomycin, 55 μ mol l −1 β -mercaptoethanol, 1 × Protein Transport Inhibitor Cocktail (eBioscience)), and were incubated at 37 °C with 5% CO 2 for 5 h. The T helper cells (T H 1, T H 2 and T H 17) were detected using Intracellular Fixation and Permeabilization Buffer Set (eBioscience) as per manufacturer's instructions.
Labelled cells were analysed immediately or fixed in 1.5% PFA. 7AAD (eBioscience) or Ghost Dye (Tonbo) was used as viability dyes for fresh or fixed cells, respectively.
Absolute cell numbers were quantified using liquid counting beads (BD Biosciences). Data were acquired using a FACS CantoII (BD Biosciences) and analysed with either FlowJo v10.0 or FACS Diva v8.0 software.
Cell sorting and RNA isolation for RNA-seq. To obtain tumour-associated CD31 + endothelial cells, E0771 breast tumours were dissociated into single-cell suspensions by a similar method as described in the 'Tumour dissociation' section, except that a Mouse Tumour Dissociation kit (Miltenyi) was used instead of collagenase III, in order to obtain a higher yield and increased viability of CD31 + cells. Also, CD31 MicroBeads (Miltenyi) were used to enrich for tumour endothelial cells through magnetic cell separation as per manufacturer's protocol. Dead cells and debris were excluded by FCS, SSC and 7AAD staining profiles. All cell-sorting experiments were performed using an Arial Cell Sorter (BD Biosciences). The CD31 + cells were sorted directly into TRIzol LS (Thermo Fisher), and RNA was extracted using the standard protocol for TRIzol RNA Extraction.
After RNA purification, MATQ-seq was performed to amplify the whole transcriptome 27 . The input and yield of each sample was determined by qPCR after 2nd strand synthesis. To obtain similar cDNA yield and decrease PCR bias, we adjusted the PCR cycle number for each sample based on the qPCR results.
Sequencing libraries were prepared from 1 ng of purified double-strand cDNA with the Illumina Nextera XT DNA Library Prep Kit per supplier's protocol. Cluster generation was performed using the Illumina Nextseq 500/550 high output v2 kits and sequenced on the Illumina Nextseq 500 equipment. In vitro treatment of IFNγ and soluble CD40 ligand (sCD40L). The HUVEC or TIME cell lines were plated at 3,000 cells cm −2 in culture plate containing VEGF endothelial complete medium (LifeLine) for 10 h. The cells were then treated with IFNγ (1,000 U ml
; R&D Systems) for 20 h or sCD40L (100 ng ml ; Tonbo) for 4 h before RNA isolation. The expression levels of VEGFA, ICAM1, SELE , CXCL9, CXCL10 and CXCL11 were measured using quantitative PCR with reverse transcription (qRT-PCR). RNA isolation and qRT-PCR. For cells cultured in vitro, RNA isolation was performed with the Quick-RNA MiniPrep Plus Kit (Zymo). Reverse transcription was performed using the High Capacity RNA-to-cDNA Master Mix (Applied Biosystems), and qRT-PCR was performed using PerfeCTa SYBR Green FastMix (Quanta) in a 7500 Real time PCR system (Applied Biosystems).
The xenograft tumours were snap-frozen with liquid nitrogen immediately after resection, and homogenized with Precellys Lysing kits (Bertin Instruments). Next, total RNA was extracted using standard TRIzol RNA extraction protocol. The cDNA was synthesized with SuperScript III First-Strand Synthesis System (Thermo Fisher), and qRT-PCR was performed using PerfeCTa SYBR Green FastMix in a CFX Connect Real-Time PCR Detection System (BioRad).
Samples were amplified by 40 cycles of 10 s at 95 °C and 30 s at 60 °C. Results were calculated by the change-in-cycling-threshold (Δ Δ C t ) method as follows (relative to the reference control gene B2M and Gapdh, encoding β -2-microglobulin and glyceraldehyde phosphate dehydrogenase, respectively): -Δ Δ C t = -(Δ C t treatment -Δ C t control), where Δ C t = C t target -Δ C t reference.
The sequences of primers used can be found in Supplementary Table 6 . Immunofluorescence staining. To prepare frozen sections, the fixed tissues were incubated in 30% sucrose in PBS (w/v) overnight, and frozen in optimum cutting temperature gel (Tissue-Tek; Sakura). Sections of 6-μ m in thickness were cut on Leica CM1850 cryotome.
For paraffin-embedded blocks, 3-μ m thick sections were deparaffinized and treated with a heat-induced antigen retrieval Tris-EDTA (pH 9.0) solution. To reduce the background, the sections were immersed in the 100 mmol l −1 NH 4 Cl for 10 min and washed with running water for 5 min.
Slides were blocked in PBS with 10% normal serum (Jackson Laboratory), 1% BSA, and 0.3% Triton X-100 (Millipore) for 1 h at 20 °C. Primary antibodies were incubated overnight at 4 °C in the blocking solution. Secondary antibodies were added into the blocking solution and incubated for 1 h at 20 °C. Nuclei were stained with 1 μ g ml −1 DAPI (4,6-diamidino-2-phenylindole; Thermo Fisher), for 2 min at 20 °C. Excess antibodies were removed by washing for 5 min in PBS with 0.5% Tween-20 (Millipore). The slides were then washed and coverslips were mounted, using ProLong Gold anti-fade reagent (Thermo Fisher). Primary antibodies included: anti-PDGFRβ (ab32570), anti-CD31 (ab28364), anti-Hif-1α (EPR16897; all from Abcam); anti-CD31 (clone MEC13.3), anti-mouse panendothelial cell antigen (clone MECA-32), anti-VCAM1 (clone 429; all from Biolegend); anti-Ki-67 (clone M-19; Santa Cruz); anti-NG2 (ab5320; Millipore); anti-VE-cadherin (AF1002; R&D Systems). Secondary antibodies included: alexa-fluor-488 goat anti-rabbit, alexa-fluor-594 goat anti-rabbit (both from Jackson Laboratory), alexa-fluor-488 chicken anti-rabbit, alexa-fluor-594 chicken anti-goat (both from Thermo Fisher). Stained sections were visualized by a Carl Zeiss Axioskop2 plus microscope using × 10, × 20 or × 40 objectives, or scanned with Zeiss Axioscan.Z1. The whole-section imaging was performed by an independent researcher who was blind to sample group allocation. Image analysis. Hypoxia levels were quantified as pimonidazole + pixels or Hif-1α + pixels divided by the DAPI + pixels.
letter reSeArCH
For pericyte coverage quantification, vessels were counted manually in five independent ~ 0.4 mm 2 fields at × 20, and percentage of vessels covered by pericytes = pixels of CD31 + cells attached by NG2 + cells / total pixels of CD31 + cells. For analysis of leakiness in addition to Evans blue assay, the diffused dextran area per section was quantified using CellProfiler.
Vessel area and density were quantified by analysis of more than 1,000 vessels from each mouse. The vessel density and colocalization were analysed automatically using CellProfiler. The computational modelling of T H 1-skewed CD4 + -TLs localization was performed with R programming language. To generate a simulated placement of CD4 + -TLs for null hypothesis, two random anchor points were placed on the edge of the tumour section, and a random point located between the two anchor points was chosen. The number of simulated points was equal to the number of actual T H 1-skewed CD4 + -TLs in the section in each round of simulation. The mean Euclidean distances between simulated points to the nearest lectin + vascular structure was measured, and mean distances generated from 10,000 rounds of simulation defined a distribution of mean distances one would observe for non-preferentially localized CD4 + -TLs in relation to lectin + tumour-associated vessels. This was then compared to the mean distance distribution between actual CD4 + -TLs and lectin + vessels on each tumour section. Bioinformatic analysis. The RNA-seq reads were mapped and quantified using the STAR RNA-seq aligner (v2.4.1d) 28 , and RSEM software package (v1.2.28) 29 , respectively. Mouse genome and gene annotation (GRCm38.83) was supplied at the genome index generation step. 'DEseq2' R package 30 was used to normalize the gene expression matrix.
Gene set enrichment analysis (GSEA) 31 and KEGG Orthology-Based Annotation System (KOBAS) v2.0 (ref. 32 ; http://kobas.cbi.pku.edu.cn/) were used to perform the functional enrichment analysis as indicated in the appropriate figure legend and Methods text. The enriched gene ontology terms were visualized using REVIGO 33 (http://revigo.irb.hr). The single-sample GSEA projection (ssGSEA) 34 was used to calculate separate enrichment scores for each pairing of a sample and gene set in Molecular Signatures Database (MSigDB). ssGSEA (v7) and GSEA (v15.2) analyses were performed using GenePattern (http://genepattern.broadin stitute.org/). GSEA was performed using 10,000 iterations collapsing probes to the highest value if necessary. For paired analysis between PDXs and the original patient tumours, a pimonidazole-based hypoxia signature was obtained from a 32-gene set that correlates with higher pimonidazole staining in human tumours 35 . Bladder cancer data were obtained from GSE67312. Breast cancer data were combined from GSE32531 and GSE41685, and only orthotopic xenograft samples were included. Liver cancer data were obtained from GSE55828. Ovarian cancer data were obtained from GSE56920. For unpaired analysis of breast cancer PDXs, data from GSE34412 were used. In addition to the pimonidazole signature, two other hypoxia-related signatures were used: a 26-gene hypoxia signature that predicts benefit from hypoxiamodifying therapy 36 , and a 13-gene VEGF signature associated with metastasis 15 .
In analysing the correlation between CD4
+ -TL number with hypoxia signature and (∑ GPAGs − ∑ PPAGs) in different solid tumour types, the percentages of CD4 + -TLs were estimated by CIBERSORT of the TCGA RNA-seq dataset. TCGA RNA-seq data were downloaded from UCSC Cancer Genome Browser (https:// genome-cancer.ucsc.edu/), and used as input for CIBERSORT to estimate the relative abundance of CD4 + -TLs (naive CD4 + T cells, memory resting CD4 + T cells and memory activated CD4 + T cells) among 22 leukocyte compositions. We used 1,000 permutation and disabled quantile normalization. Statistical methods. Sample sizes are denoted in figures or figure legends, and refer to number of animals unless otherwise noted. Data are generally expressed as mean ± s.e.m. In box-whisker plots, the upper and lower hinges correspond to the first and third quartiles, and the upper and lower whiskers are highest and lowest values that are within 1.5 × IQR (interquartile range) of the hinge.
In most in vivo experiments, group sizes were determined based on the results of preliminary experiments and no statistical method was used to predetermine sample size. Experiments were repeated twice independently, and the data are combined and presented. Extended Data Fig. 3l is the only exception: one representative experiment from two is shown. For the dot plots of immunostaining results, smaller dots without an outline are values from individual fields (~ 0.4 mm 2 fields at × 20), and circles that are outlined represent mean values taken over multiple fields from the same mouse, unless otherwise noted. The statistical tests were performed by comparing the individual animals. All in vitro experiments were repeated independently for three times (batches). The P values in these in vitro experiments were determined on the basis of biological replicates (with technical replicates averaged within each biological replicate).
All samples that met proper experimental conditions were included in the analysis. Data were analysed with Prism 7 software (GraphPad) or R programming language (v3.2.0). Statistical significance was determined using a two-tailed MannWhitney U-test or Student's t-test. F-test was conducted before Student's t-test to compare the variance of two samples. Welch's correction is applied to Student's t-test if the null hypothesis of equality of variances is rejected. Comparison of tumour-growth curves were assessed by two-way analysis of variance (ANOVA). Survival analyses were evaluated by Kaplan-Meier curves and the log-rank (Mantel-Cox) test. P values lower than 0.05 were considered statistically significant. Code availability. The source codes and data of bioinformatics analysis were deposited to https://github.com/lintian0616/vesselNormalization. All other Source Data are provided with the online version of the paper. Data availability. The RNA-seq data have been submitted to the Gene Expression Omnibus under accession number GSE89758. . P values were calculated using two-tailed unpaired Mann-Whitney U-test (c-f, i), two-tailed one-way analysis of variance (ANOVA) (j) or permutation (g). NS, not significant.
